^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Bria-OTS
i
Other names: Bria-OTS
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BriaCell
Drug class:
Immunostimulant, T-cell stimulant
Related drugs:
1year
Engineering semi-allogeneic whole cancer vaccines with enhanced immunogenicity for the treatment of advanced solid tumors (AACR 2023)
We sought to harness gene-modified tumor cells as a vaccine platform and developed cancer vaccines composed of breast cancer cells expressing GM-CSF (SV-BR-1-GM). Different types of cancer vaccines have been developed with moderate success, often hampered by lack of strong immunogenicity and complex manufacturing. BriaCell’s Bria OTS provides a solution by increasing vaccine immunogenicity and decreasing manufacturing costs while personalizing the therapy based on matching the patient’s HLA type.1.Lacher MD et al, Front Immunol. 2018 May 15;9:776
Metastases
|
CD4 (CD4 Molecule) • CSF2 (Colony stimulating factor 2) • IFNA1 (Interferon Alpha 1) • IL7 (Interleukin 7) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
|
CSF2 expression
|
Bria-IMT (SV-BR-1-GM) • Bria-OTS
Share via
